- Research article
- Open Access
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Arthritis Research & Therapyvolume 8, Article number: R29 (2006)
The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34–0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97–2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13–4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications.
When initiated early in rheumatoid arthritis (RA), significant control of joint inflammation and damage and improvement in physical function are obtained with disease modifying antirheumatic drugs (DMARDs), alone or in combination with tumor necrosis factor (TNF) antagonists . Three TNF antagonists, infliximab, etanercept, and adalimumab, have demonstrated efficacy in RA [2–4] and are commercially available. The World Health Organization Collaborating Center consensus proposed that RA patients with active disease who have failed to respond to an adequate course of DMARDs are eligible for anti-cytokine therapy . Other guidelines recommend a similar indication for these agents. In other forms of chronic arthritis, TNF antagonists are also recommended for patients whose disease does not respond to non-steroidal anti-inflammatory drugs or DMARDs [6–9].
In RA, evidence based on clinical trials suggests that these three drugs are equally effective, though they have distinct structural, pharmacokinetic, and pharmacological properties , and differences in their modes of action . Comparable effectiveness has also been found in clinical settings . Nevertheless, a proportion of patients do not benefit from treatment with a certain TNF antagonist, and thus the use of a second antagonist when the first has failed is advocated based on a few clinical reports of small numbers of patients [13–16]. For the other forms of chronic arthritis, this information is still lacking; whether a second TNF antagonist would be effective is a relevant clinical question.
In February 2000, the Spanish Society of Rheumatology (SER) launched a registry (Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología (BIOBADASER)) for patients with rheumatic conditions treated with biologics, including TNF antagonists. Over the last four and half years, 4,706 patients from 95 hospitals have been included in this registry and have been actively followed. Although the emphasis of the registry is drug safety, information on discontinuation of TNF antagonists for any cause is gathered as well. In the present study, we analyze the drug survival rates of TNF antagonists, as a surrogate for their effectiveness, in 488 patients with rheumatic diseases who had switched from one TNF antagonist to another.
Materials and methods
BIOBADASER methodology has been described previously  and is detailed the BIOBADASER website . Briefly, BIOBADASER is a registry established in February 2000 for the active long-term follow-up and assessment of the safety of biological response modifiers in rheumatic patients. The registry, which is supported by the SER and funded, in part, by the Spanish Agency for Medicines and Medical Devices, notes relevant adverse events occurring during and after treatment. Patients registered in BIOBADASER are those with rheumatic diseases being treated with any of the approved biological response modifiers in the participating centers; participation is voluntary. Infliximab was made available for clinical use in August 1999, etanercept in April 2003 and adalimumab in September 2003 (some patients actually started on adalimumab before general availability, as part of a clinical study, and their data were entered in BIOBADASER once the study ended as all relevant variables had been collected properly). SER guidelines do not propose molecule-specific criteria for prescribing any of the TNF inhibitors.
Data collected systematically include gender, date of birth, diagnosis, date of diagnosis, treatment type, and dates of commencement and of discontinuation. Should a patient discontinue the treatment, the main reason for stopping is also recorded (inefficacy, adverse event, or other causes). When a patient has a relevant adverse event, additional data are registered, including the date of occurrence, type and classification of event, outcome, concomitant treatment, and co-morbidity. The quality of our database is assured by a clear definition of its aim, an optimized number of variables, and an easy method of data collection that allows consistency checks. Incompleteness and agreement of data with patient charts are assessed in site by annual audits of 10% of all patients registered. All errors are corrected accordingly following these audits, yielding an expected underreporting of 11% of actual discontinuations or adverse events. Data from centers in which there is proved incompleteness of data are censored at the time of the last reliable information. The registry was approved by the Spanish Medicines Agency (Ministerio de Sanidad y Consumo), and the information regarding patients was gathered in the registry according to the present official regulations on data protection. The number of patients receiving biologics for rheumatic diseases registered in BIOBADASER represents around 60% of the total population treated in Spain.
The cumulative rate of discontinuation was calculated using the actuarial method with multiple-failure per patient. Survival curves in figures are presented with patients starting each time interval, but not with failures, data which are included in the survival estimates for simplicity. The time of starting the TNF antagonist was time 0. The log-rank test was used to compare survival curves, and Cox regression models were used to assess the difference between groups and to measure association with risk factors for discontinuation. The variables included in the Cox models for discontinuation of first treatment were sex, age group, TNF-antagonist, year of first treatment with a TNF-antagonist, and diagnosis (RA, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, or others). The variables included in the Cox models for discontinuation of the second treatment were the same plus the main reason of discontinuation of the first treatment. The bivariate models included primarily only the dependent variable and one independent variable at a time. Subsequently, all variables reaching a p value < 0.10 were included in multivariate models to assess independent associations and better ascertain interactions between variables. Additionally, we wanted to identify the characteristics of patients with longer survival of the second course of treatment (more than one year). For this analysis we used logistic regression, bivariate and multivariate analyses, in which the dependent variable was long duration of the second treatment and the explanatory variables those listed above.
A total of 3,130 women and 1,576 men using TNF antagonists with an overall age of 50 ± 15 years (mean ± standard deviation) were registered in BIOBADASER from the starting date in February 2000 until September 2004. Diagnoses were 68% RA, 11% ankylosing spondylitis, 10% psoriatic arthritis, and the remaining 11% a variety of other chronic inflammatory rheumatic conditions. There was a total of 5,263 treatments with TNF antagonists, and 1,221 discontinuations. The reasons for discontinuation were adverse events in 562 (46%), inefficacy in 465 (38%), patients' decision in 86 (7%), physicians' decision in 38 (3%), improvement in 14 (1%), pregnancy in 10 (1%), poor vein access in 8 (1%), and renal failure secondary to previously known amyloidosis in 3 (0.5%). Fifteen patients were lost to follow up. A total of 488 patients were treated with more than one TNF antagonist (441 patients with two, and 47 with at least three), of whom 385 had RA. The total exposure rate was 9,269 patient years: 7,109 patient years for infliximab, 1,863 patient years for etanercept, and 295 patient years for adalimumab.
Drug survival at first year of treatment depended not only on whether it was the first or successive treatment (Figure 1), but also on the agent used. In this sense, survival of the first TNF antagonist after one year of treatment was slightly lower, but statistically significant, for infliximab (0.81 (range 0.79 to 0.82)) compared to etanercept (0.88 (0.85 to 0.91)) and adalimumab (0.87 (0.82 to 0.91)). The drug survival is consistently lower when the drugs are used as a second treatment, and statistically lower for infliximab (0.34 (0.19 to 0.51)) than for etanercept (0.76 (0.68 to 0.81)) or adalimumab (0.67 (0.42 to 0.83)). However, infliximab treatments were first started 40 and 50 months before any etanercept and adalimumab treatments, respectively. A similar trend was seen for the third TNF antagonist used, but the numbers were too small for a meaningful analysis.
Reasons for discontinuation of the three TNF antagonists were similar (Table 1); adverse events were the most frequent reason (48%) for discontinuing the agent used in the first place. The kappa value for concordance between the reasons for discontinuation of the first versus the second treatment was 0.29. Survival of the second TNF antagonist was better (p = 0.007) if the first one was replaced because of an adverse event (Figure 2).
Replacement of infliximab by etanercept
There were 356 patients switched from infliximab to etanercept. The first year survival of etanercept was 0.78 (95% confidence interval (CI): 0.71–0.83). The median treatment duration to discontinuation of infliximab was 0.56 (P25–75: 0.46–0.68) years, and of etanercept 0.24 (P25–75: 0.16–0.34) years (p < 0.001). There were no statistical differences in the reasons for discontinuing infliximab or etanercept; these were inefficacy in 57% of the cases and adverse events in 42%.
Replacement of etanercept by infliximab
Fifty-two patients who failed to respond to etanercept as the first TNF antagonist received infliximab. First year survival of infliximab was 0.28 (95% CI: 0.15–0.42). The median treatment duration to discontinuation of etanercept was 0.51 (95% CI: 0.19–0.84) years, and of infliximab 0.51 (95% CI: 0.19–0.66) years. There were differences, however, in the reasons for discontinuing etanercept and infliximab. Etanercept was discontinued in 82% of the cases because of inefficacy, and infliximab was discontinued due to adverse events in 54% of cases (χ2 p = 0.015).
Replacement of infliximab by adalimumab
Thirty-three patients switched from infliximab to adalimumab. First-year survival of adalimumab was 0.69 (95% CI: 0.43–0.85). The median treatment duration to discontinuation of infliximab was 0.73 (95% CI: 0.04–0.95) years, and this duration was 0.18 (95% CI: 0.12) years for adalimumab. The reasons for discontinuation were similar for the two agents.
Replacement of etanercept by adalimumab
Only 14 patients switched from etanercept to adalimumab, of whom two had discontinued as of analysis day. First year survival of adalimumab was 0.75 (95% CI: 0.31–0.93). The median treatment duration to discontinuation of etanercept was 0.55 (95% CI: 0.23–1.29) years, and 0.06 (no 95% CI available) years for adalimumab (p = 0.003). Reasons for discontinuation were similar for etanercept and adalimumab.
Risk factors for discontinuation and factors associated with a prolonged second course of treatment
There are no clear differences in the survival of the second TNF antagonist among patients with different diagnosis, although there seems to be a trend toward worse survival in the second trial of a TNF antagonist in RA, and even more in juvenile idiopathic arthritis (Table 2).
There are also no differences in survival at one year depending on the year of start of the first TNF antagonist: 84% in year 2000, 82% in year 2001, 81% in year 2002, and 83% in year 2003. According to the results of the bivariate Cox regression models, the factors with the strongest association with discontinuation of the first treatment were therapy with infliximab (hazard ratio (HR) 1.50 (95% CI: 1.27–1.77)) and a diagnosis of RA (HR 1.36 (95% CI: 1.18–1.56)). We did not find any interaction between diagnosis and individual TNF antagonist. Being older than 60 (HR 1.21 (95% CI: 1.07–1.38)) and female (HR 1.25 (95% CI: 1.10–1.43)) were not independently associated with discontinuation, as demonstrated by the introduction of the diagnosis of RA in the models. Infliximab has the strongest association with discontinuation of the second treatment (HR 3.83 (95% CI: 2.58–5.68)). Having suspended the first treatment as a consequence of adverse events reduced the probability of discontinuation of the second treatment by half (HR 0.54 (95% CI: 0.34–0.84)).
In this study, we analyzed drug survival in patients switching TNF antagonists for chronic arthritis. Overall, our results show that the probability of retaining a second TNF antagonist is lower than that of retaining the first one. Of further interest, probability of survival was influenced by diagnosis, reason for drug replacement, and perhaps the molecule used.
Measuring the effectiveness of drugs through observational databases has some limitations, such as assignment of treatment, patient selection bias, and the absence of a washout period . Nonetheless, drug survival can be taken as a sensible indicator of its effectiveness in the clinical setting, and community-based studies that analyze continuation of treatment with different DMARDs are common in rheumatology [20–25]. Furthermore, withdrawal rates of DMARDs in observational studies are similar to those reported in clinical trials . This type of analysis may also demonstrate the effectiveness of new therapies .
In a study of RA conducted in seven Swedish clinical centers, discontinuation rates at 24 months of infliximab and etanercept were 25% and 21%, respectively, in agreement with our results . This observation is in contrast with the 0% discontinuation rate reported after 15 months of treatment with infliximab and etanercept in a university clinic in the USA . Parameters other than efficacy and safety, such as co-morbidity, co-medications , costs, availability of other therapies, patients' and physicians' expectations, and adherence to treatment , are at play. Adherence is also important in this type of analysis. It is a reflection, among other elements, of the patient's compliance , pertinent in the case of molecules with different modes of administration, and of variable costs in the diverse health systems. Whether all these factors explain the dissimilarity in the drug survival of TNF antagonists needs further elucidation. Of note, TNF antagonists have similar survival in the different forms of chronic arthritis.
In a previous study, improvement was reported in 8 of 14 RA patients who switched from infliximab to etanercept or from etanercept to infliximab (6 patients) because of adverse events or lack of efficacy . In another study, improvement was observed in 20 patients replacing etanercept with infliximab . The efficacy and safety of four infusions of infliximab in patients failing to respond to etanercept have been described as well . Finally, improvement in inflammation parameters was seen in 12 of 14 patients switching from infliximab to etanercept in another recent study . Information regarding switching to or from adalimumab is not available yet. In the present study, efficacy based on evaluation of clinical parameters was not investigated. Instead, effectiveness was assessed as the probability of drug survival in a large number of patients. Our results indicate that switching TNF antagonists may be effective in a selected group of patients.
Older age emerged as a predictor of shortened drug survival. This is not surprising in light of older patients' recognized risk of suffering medication-related problems .
Unexplained is the lower survival of infliximab when compared to other TNF antagonists, especially when used for replacement therapy. Bias towards the use of new drugs in the most severe or non-responder patients  distorts assessment of efficacy. This bias disappears as the pool of patients completes the exposure to the new agent . It should be kept in mind that infliximab treatment was started 40 and 50 months before etanercept and adalimumab, respectively. When infliximab was made available, it was first used in the most severe cases, in those patients in whom good drug survival was not very much expected. As other TNF antagonists became available, patients with a less severe disease were offered these treatments, thus improving overall drug survival (Figure 3). In addition, availability of other TNF antagonists may have led to early drug discontinuation and replacement with a novel agent. In all probability, discontinuation rates of the new TNF antagonists in clinical practice will increase with the arrival of other therapeutic agents. Also, a key variable among the members of the TNF antagonist class is the route of administration . Infusion reaction occurs early in the follow-up of patients with infliximab, which cuts the drug survival dramatically, especially if taking into account that, in this case, the initiation and discontinuation date are the same, something very unusual with other preparations. Furthermore, the intravenous route is generally related to more adverse events. Also, patients may have preferences for particular routes, for example, subcutaneous, and so ask the physician for a change, although this was the main reason for discontinuation in only four cases.
In our study, in contrast with others, differences in cost were not a major consideration for using one or another TNF antagonist, because of the free, unrestricted access to the drugs, provided to all patients by the National Health System.
Our study supports the replacement of TNF antagonists in a select group of patients with chronic arthropathies who require continuous therapy. Considering the arrival of new medications, this issue will deserve reassessment because of greater expectancies of patients and doctors.
Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología
disease modifying antirheumatic drugs
Spanish Society of Rheumatology
tumor necrosis factor.
Breedveld FC, Kalden JR: Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis. 2004, 63: 627-633. 10.1136/ard.2003.011395.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 354: 1932-1939. 10.1016/S0140-6736(99)05246-0.
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259. 10.1056/NEJM199901283400401.
den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, et al: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002, 29: 2288-2298.
Emery P, Reginster JY, Appelboom T, Breedveld F, Edelmann E, Kekow J, Malaise M, Mola EM, Montecucco C, Sanda M, et al: WHO Collaborating Center consensus on anti-cytokine therapy in rheumatoid arthritis. Rheumatology. 2001, 40: 699-702. 10.1093/rheumatology/40.6.699.
Wendling D, Toussirot E: Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother. 2004, 5: 1497-1507. 10.1517/14656518.104.22.1687.
Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D: ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003, 62: 817-824. 10.1136/ard.62.9.817.
Gottlieb AB, Antoni CE: Treating psoriatic arthritis: how effective are TNF antagonists?. Arthritis Res Ther. 2004, 6 (Suppl 2): S31-35. 10.1186/ar1016.
Cron RQ: Current treatment for chronic arthritis in childhood. Curr Opin Pediatr. 2002, 14: 684-687. 10.1097/00008480-200212000-00006.
Scallon BJ, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002, 301: 418-426. 10.1124/jpet.301.2.418.
Arend WP: The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002, 65: 16-21.
Geborek P, Cmkic M, Petersson IF, Saxne T: Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002, 61: 793-798. 10.1136/ard.61.9.793.
Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, Euller-Ziegler L: Etanercept – infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. Presse Med. 2002, 31: 1836-1839.
Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, Cohen SB, Gangnon RE, Schiff MH: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol. 2004, 31: 1098-1102.
Efficacy and toxicity of infliximab (remicade) in patients with rheumatoid artritis:xperience in a routine clinical practice. [http://www.abstracts2view.com/eular/view.php?nu=EULAR2L1_2002FRI0143]
Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, Pontikaki I: Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum. 2004, 51: 301-302. 10.1002/art.20242.
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003, 48: 2122-2127. 10.1002/art.11137.
BIOBADASER website. [http://biobadaser.ser.es]
Krishnam E, Fries JF: Measuring effectiveness of drugs in observational databanks: promises and perils. Arthritis Res Ther. 2004, 6: 41-44. 10.1186/ar1151.
Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990, 17: 994-1002.
Pincus T, Marcum SB, Callahan LF: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. 2. Second line drugs and prednisone. J Rheumatol. 1992, 19: 1885-1894.
Morand EF, McCloud PI, Littlejohn GO: Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol. 1992, 19: 704-708.
De La Mata J, Blanco FJ, Gomez-Reino JJ: Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients. Ann Rheum Dis. 1995, 54: 881-885.
Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LBA, van Riel PL: Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol. 1992, 31: 253-258.
Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology. 2000, 39: 975-981. 10.1093/rheumatology/39.9.975.
Suarez Almazor ME: In the quest of the holy grail: Efficacy versus effectiveness in rheumatoid arthritis. J Rheumatol. 2002, 29: 209-211.
Power DJ, Villanueva I, Yocum DE, Nordensson KA: Comparison of survival curves between infliximab and etanercept: medication discontinuation as event [abstract]. Arthritis Rheum. 2002, 46: S171-
Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995, 9: 619-3. 10.1016/S0950-3579(05)80305-X.
Shelton PS, Fritsch MA, Scott MA: Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging. 2000, 16: 437-450. 10.2165/00002512-200016060-00004.
Petri H, Urquhart J: Channeling bias in the interpretation of drug effects. Stat Med. 1991, 10: 577-581.
Wolfe F, Michaud K, Stephenson B, Doyle J: Toward a definition and method of assessment of treatment failure and treatment effectiveness: The case of leflunomide versus methotrexate. J Rheumatol. 2003, 30: 1725-1732.
Schwartzam S, Morgan GJ: Does route of administration affect the outcome of TNF antagonist therapy. Arthritis Res Ther. 2004, 6 Suppl 2: S19-S23. 10.1186/ar996.
We want to acknowledge the remarkable work of Raquel Ruiz as the monitor of the registry. We also want to thank Rocío González for help with statistical analyses. This work could have not been completed without the contribution of a large number of Spanish rheumatologists, and the support of the Spanish Agency for Medicines and Medical Devices. We would like to thank Dr Paul Kretchmer at San Francisco Edit for his assistance in editing this manuscript.
The BIOBADASER database is supported by the Spanish Society of Rheumatology (SER). The current study was funded, in part, by the Agencia Española del Medicamento y Productos Sanitarios (Agency for Medicines and Medical Devices; a part of the Spanish Ministry of Health).
The following is a list of contributors (and centers) in BIOBADASER, with the steering committee members identified with an asterisk.
Alba Erra, Sara Marsal (Ciudad Sanitaria Vall D'hebron); Mónica Fernández Castro, Juan Mulero*, Jose Luis Andreu (Clínica Puerta de Hierro); Manuel Rodríguez Gómez (Complejo Hospitalario de Ourense); Marta Larrosa Padro, Enrique Casado (Consorci Hospitalari del Parc Tauli); Elena Leonor, Sirvent Alierta, Delia Reina, Carmen García Gómez (Hospital de Bellvitge); Beatriz Joven Ibañez, Patricia Carreira Delgado (Hospital 12 de Octubre); Ma Victoria Hernández (Hospital Clinic i Provincial); Estibaliz Loza (Hospital Clínico Universitario San Carlos); Alberto Alonso Ruiz, Esther Uriarte Itzazelaia (Hospital de Cruces); Lucia Pantoja Zarza, Ma Valvanera Pinillos Aransay (Hospital del Bierzo); Teresa Mariné Hernández (Hospital de L'Esperit Sant); Rosario García de Vicuña Pinedo, Ana Ma Ortiz García, Isidoro González Álvaro, Armando Laffon*, Jose Ma Álvaro-Gracia* (Hospital Universitario de La Princesa); César Díaz López, Arturo Rodríguez de La Serna (Hospital de La Santa Creu I Sant Pau); Eduardo Loza Cortina (Hospital de Navarra); Ma Victoria Irigoyen Oyarzabal, Inmaculada Ureña Garnica, Virginia Coret Cagigal (Hospital General Carlos Haya); Paloma Vela Casasempere, Eliseo Pascual* (Hospital General Universitario de Alicante); Miquel Ángel Belmonte Serrano, Juan Beltran Fabregat, Juan José Lerma (Hospital General de Castellón); Myriam Liz Graña, Juan José Gómez-Reino* (Hospital Clínico Universitario de Santiago); Saul Mario Gelman Aizen (Hospital General de Manresa); Elena Ciruelo Monge, Eva Tomero Muriel (Hospital General de Segovia); Juan Carlos Cobeta García (Hospital General de Teruel Obispo Polanco); Encarnación Saiz Cuenca, José Galvez Muñoz (Hospital General Morales Meseguer); Gerardo Iglesias de La Torre (Hospital General Rio Carrión); Rosa Roselló Pardo, Carlos Vázquez Galeano (Hospital General San Jorge); Juan Pablo Valdazo de Diego (Hospital General Virgen de La Concha); Xavier Tena Marsá*, Vera Ortiz Santamaría (Hospital Universitari Germans Trias i Pujol); Manuel Fernández Prada, José Antonio Piqueras, Jesús Tornero* (Hospital General Universitario de Guadalajara); Laura Cebrián Méndez, Luis Carreño* (Hospital Gregorio Marañón); Juan José García Borras (Hospital La Fe); Francisco Javier Manero Ruiz (Hospital Universitario Miguel Servet); Manel Pujol Busquets, Josep Granados Duran (Hospital Mutua Terrassa); Jose Luis Cuadra, F Javier Paulino Tevar, Marcos Paulino Huertas (Hospital Nuestra Señora del Carmen); Olga Maiz, Estibaliz Barastay, Manuel Figueroa* (Hospital de Donosti); Carmen Torres, Montserrat Corteguera Coro (Hospital Nuestra Señora de Sonsoles); Carlos Rodríguez Lozano, Félix Francisco Hernández, Iñigo Rua Figueroa Fernández (Hospital de Gran Canaria Dr Negrín); Oscar Illera Martín, Antonio C Zea Mendoza, Paloma García de La Peña Lefebvre, Marta Valero Expósito (Hospital Ramón y Cajal); Emilia Aznar, Ricardo Gutiérrez (Hospital Reina Sofía); Ana Cruz Valenciano, Manuel Crespo Echeverria, Félix Cabero Del Pozo (Hospital Severo Ochoa); Ma Teresa Ruiz Jimeno (Hospital Comarcal Sierrallana); Jordi Fiter Aresté, Luis Espadaler Poch (Hospital Son Dureta); Juan Carlos Vesga Carasa, Eduardo Cuende Quintana (Hospital Txagorritxu); Sagrario Sánchez Andrada, Vicente Rodríguez Valverde* (Hospital Universitario Marqués de Valdecilla); Ivan Ferraz Amaro, Tomas González García (Hospital Universitario de Canarias); José Luis Marenco*, Eduardo Rejón (Hospital Universitario de Valme); Eduardo Collantes Estevez, M Carmen Castro Villegas (Hospital Universitario Reina Sofía); Blanca Hernández, José V Montes de Oca Mercader, Federico Navarro Sarabia, Francisco Javier Toyos Saenz de Miera (Hospital Universitario Virgen Macarena); Carlos Marras Fernández-Cid, Luis Francisco Linares Ferran, Juan Moreno Morales (Hospital Virgen de La Arrixaca); Carmen González-Montagut (Hospital Virgen de La Luz); Ángel García Aparicio (Hospital Virgen de La Salud); Rafael Cáliz Cáliz, Carmen Idalgo Tenorio (Hospital Virgen de Las Nieves); Amalia Sánchez-Andrade Fernández (Hospital Xeral-Calde); Tatiana Cobo, Azucena Hernández, Emilio Martín-Mola* (Hospital La Paz); Xavier Arasa Fava (Hospital de Tortosa); José Raúl Noguera Pons, Francisco J Navarro Blasco, Juan Víctor Tovar Beltran (Hospital General Universitario de Elche); José Carlos Rosas Gómez de Salazar, Gregorio Santos Soler (Hospital del SVS de Villajoyosa); Isabel Ibero Díaz, Vega Jovani Casado, Raquel Martín Domenech (Hospital General de Elda); Jordi del Blanco Barnusell (Hospital Sant Jaume de Calella); Miguel Ángel Abad Hernández, Maria Torresano Andrés (Hospital Virgen del Puerto); Gaspar Pérez Lidon, Manuel Tenorio Martín (Hospital del Insalud Ceuta); Inmaculada Bañegil (Hospital de Mendaro); Joan Maymo Guarch, Carolina Pérez García, Jordi Carbonell* (IMAS Hospital de l'Esperança y del Mar); Víctor Eliseo Quevedo Vila (Hospital Comarcal de Monforte); Javier Rivera Redondo, Teresa González Hernández (Instituto Provincial de Rehabilitación); José Manuel Rodríguez Heredia, Ángel Gallegos Cid, Jesús García Arroba Muñoz, Miguel Cantalejo Moreira (Hospital Universitario de Getafe); Raquel Almodovar, Javier Quiros Donate, Pedro Zarco Montejo, Ramón Mazzucchelli (Hospital Fundación Alcorcón); Alfonso Corrales Martínez (Hospital Comarcal de Laredo); Dolors Boquet Estruch (Hospital Arnau de Vilanova); Francisco Pérez Torres (Hospital General de Requena); José Ivorra Cortes (Hospital Gral de Onteniente); Xavier Suris Armangue (Hospital General de Granollers); Trinidad Pérez Sandoval (Hospital Virgen Blanca); Javier Calvo Catalá, Cristina Campos (Hospital General Universitario de Valencia); Maria Francisca Pina Pérez (Hospital Rafael Méndez); Cristina Hidalgo Calleja (Hospital de La Santísima Trinidad); Julia García Consuegra, Rosa Merino Muñoz (Hospital Infantil La Paz); Miquel Sala Gómez (Hospital de Figueres); Montserrat Centellas (Hospital de Mataró); José Miguel Ruiz Martín (Hospital de Viladecans); Antonio Juan Mas, Inmaculada Ros Vilamajó (Fundación Hospital Son Llàtzer); Jaime Fernández Campillo, Rocío González Molina (Hospital del SVS Vega Baja); Mauricio Minguez Vega, Gaspar Panadero Tendero (Hospital San Juan de Alicante); Jesús Ibáñez Ruan (Policlínico Vigo, SA (Povisa)); Anna Martínez Cristobal, Pilar Trenor (Hospital de La Ribera); Jenaro Graña Gil (Hospital Santa Teresa); Ma Teresa Bosque Peralta (Hospital Clínico Universitario Lozano Blesa); Ana Urruticoechea Arana (Hospital Can Misses de Ibiza); José Román Ivorra, Inmaculada Chalmeta (Hospital Universitario Dr Peset); Javier Alegre López, Bonifacio Álvarez Lario, José Luis Alonso Valdivielso, Julia Fernández Melón (Hospital General Yagüe); Ma Angeles Belmonte López (Clínica A Belmonte); Dolores Montero* (Agencia Española del Medicamento y Productos Sanitarios); Loreto Carmona* (Sociedad Española de Reumatología).
JJGR is on the Advisory Boards of Wyeth and Roche, and has received lecture fees from Abbott, Wyeth, and Shering Plough.
JJGR prepared the manuscript, which was reviewed and modified by LC. LC planned and ran the analyses. Both were the main designers of the study, helped by other members of the BIOBADASER Study group. The BIOBADASER Study group collected and checked the data without perceiving any economic reward.